The University of Texas Health Science Center at San Antonio · GeneticsAcute Myeloid Leukemia Research Lab
Mingjiang Xu · San Antonio, Texas
Research Focus
Dr. Mingjiang Xu's lab at the University of Texas Health Science Center focuses on understanding the mechanisms behind acute myeloid leukemia (AML) and hematopoietic stem cell (HSC) regulation. The research aims to identify novel therapeutic targets, like the protein PSPC1, to improve treatment outcomes for AML, a challenging blood cancer. The lab also investigates the role of RNA modifications and specific proteins in regulating stem cell function, which could lead to new treatments for hematological malignancies.
acute myeloid leukemiahematopoietic stem cellsPSPC1TET2RNA modificationscancer therapydeubiquitylationtranscription factorsmethylation pathways
Research Aims
5AIM 01Investigate the therapeutic value of PSPC1 in fighting acute myeloid leukemia (AML).
AIM 02Explore the role of the RNA m5C-MBD6-H2AK119ub deubiquitylation axis in hematopoietic stem cell regulation.
AIM 03Identify the molecular mechanisms through which PSPC1 contributes to AML pathology.
AIM 04Study the impact of TET2 mutations on hematopoietic stem/progenitor cell function.
AIM 05Develop targeted strategies to inhibit PSPC1 and improve AML treatment outcomes.
Skills the Lab Values
cell cultureRNA sequencingChIP-seqgene editing (CRISPR)Western blotflow cytometryanimal modelsmolecular cloningprotein purification
Output against the department
Publications207top 40% of dept.104th of 259
this lab
most publishedleast published
Citations8.3kbottom 44% of dept.144th of 259
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.